Literature DB >> 23904366

Regulatory effects of deguelin on proliferation and cell cycle of Raji cells.

Jin-Rong Xiong1, Hong-Li Liu2.   

Abstract

The underlying mechanism of deguelin regulating the cell cycle in human Burkitt's lymphoma cell line Raji cells in vitro, and the cytotoxicity of deguelin to Raji cells and human peripheral blood monocular cells (PBMCs) were investigated. The effects of deguelin on the growth of Raji cells were studied by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium (MTT) assay. Apoptosis was detected through Hoechst 33258 staining. The effect of deguelin on the cell cycle of Raji cells was studied by a propidium iodide method. The expression levels of cyclin D1, P21 and pRb were examined by using Western blotting. The results showed that the proliferation of Raji cells was inhibited in the deguelin-treated group, with a 24-h IC(50) value of 21.61 nmol/L and a 36-h IC(50) value of 17.07 nmol/L. Proliferation in Raji cells was inhibited significantly by deguelin, while little change was observed in PBMCs. Deguelin induced G(2)/M arrest in Raji cells. The expression of cyclin D1, P21 and pRb was dramatically down-regulated by deguelin in a dose-dependent manner. It was concluded that deguelin could inhibit the proliferation of Raji cells by arresting the cells at G(2)/M phase and inducing the cell apoptosis. Moreover, deguelin selectively induced apoptosis of Raji cells with low toxicity to PBMCs. The antitumor effects of deguelin were related to the down-regulated expression of cyclin D1, P21 and pRb proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904366     DOI: 10.1007/s11596-013-1147-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

1.  Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.

Authors:  G O Udeani; C Gerhauser; C F Thomas; R C Moon; J W Kosmeder; A D Kinghorn; R M Moriarty; J M Pezzuto
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats.

Authors:  G O Udeani; G M Zhao; Y G Shin; J W Kosmeder; C W Beecher; A D Kinghorn; R M Moriarty; R C Moon; J M Pezzuto
Journal:  Cancer Chemother Pharmacol       Date:  2001-03       Impact factor: 3.333

3.  Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro.

Authors:  Hong-Li Liu; Yan Chen; Guo-Hui Cui; Qiu-Ling Wu; Jing He
Journal:  Acta Pharmacol Sin       Date:  2005-07       Impact factor: 6.150

4.  Deguelin regulates nuclear pore complex proteins Nup98 and Nup88 in U937 cells in vitro.

Authors:  Hong-li Liu; Yan Chen; Guo-hui Cui; Qiu-ling Wu; Jing He; Wei-hua Chen; Jian-feng Zhou
Journal:  Acta Pharmacol Sin       Date:  2005-10       Impact factor: 6.150

5.  Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC).

Authors:  Dorota Dworakowska; Ewa Jassem; Jacek Jassem; Carsten Boltze; Klaus Hermann Wiedorn; Rafał Dworakowski; Jan Skokowski; Kazimierz Jaśkiewicz; Eugenia Czestochowska
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-05       Impact factor: 4.553

6.  Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway.

Authors:  Vijayalakshmi Thamilselvan; Mani Menon; Sivagnanam Thamilselvan
Journal:  Int J Cancer       Date:  2011-04-07       Impact factor: 7.396

7.  A novel natural inhibitor of extracellular signal-regulated kinases and human breast cancer cell growth.

Authors:  Ernest B Izevbigie; Joseph L Bryant; Alice Walker
Journal:  Exp Biol Med (Maywood)       Date:  2004-02

8.  A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Authors:  Young-Ah Suh; Jai-Hyun Kim; Myung A Sung; Hye-Jin Boo; Hye Jeong Yun; Sun-Hye Lee; Hyo-Jong Lee; Hye-Young Min; Young-Ger Suh; Kyu-Won Kim; Ho-Young Lee
Journal:  Cancer Lett       Date:  2013-01-21       Impact factor: 8.679

9.  Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells.

Authors:  Ho-Young Lee; Young-Ah Suh; Jerome W Kosmeder; John M Pezzuto; Waun Ki Hong; Jonathan M Kurie
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

10.  Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells.

Authors:  Bin-Chuan Ji; Chien-Chih Yu; Su-Tso Yang; Te-Chun Hsia; Jai-Sing Yang; Kuang-Chi Lai; Yang-Ching Ko; Jen-Jyh Lin; Tung-Yuan Lai; Jing-Gung Chung
Journal:  Oncol Rep       Date:  2012-01-04       Impact factor: 3.906

View more
  3 in total

1.  Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro.

Authors:  Wen Kang; Xiao Zheng; Ping Wang; Shanyu Guo
Journal:  Int J Mol Med       Date:  2018-03-05       Impact factor: 4.101

2.  Molecular interaction studies of Deguelin and its derivatives with Cyclin D1 and Cyclin E in cancer cell signaling pathway: The computational approach.

Authors:  Kiran Bharat Lokhande; Shuchi Nagar; K Venkateswara Swamy
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

3.  Deguelin, a Novel Anti-Tumorigenic Agent in Human Esophageal Squamous Cell Carcinoma.

Authors:  Yuh Baba; Yasumasa Kato
Journal:  EBioMedicine       Date:  2017-11-16       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.